Community-acquired Pneumonia Clinical Trial
Official title:
Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia. Analysis of Risk Factors and Impact on the Outcome.
I. To investigate time measurement from emergency room admission to first antibiotic
administration.
II. To evaluate risk factors for prolonged time to first antibiotic administration.
III. To correlate time measurement with Charlson comorbidity index and multimorbidity
patterns.
IV. To investigate the impact of a delayed time to first antibiotic administration on the
outcome
In this retrospective cohort study, we plan to include all patients presenting with a
community-acquired pneumococcal pneumonia at the University Hospital of Zurich between
January 1, 2006 and June 30, 2012 (6½ years). The patients will be identified either with
one or more blood culture pairs positive for S. pneumoniae or with a positive pneumococcal
urine antigen assay in combination with the clinical diagnosis of CAP, which was based on
the presence of select clinical features (e.g., cough, fever, sputum production, and
pleuritic chest pain) and is supported by imaging of the lung, usually by chest radiography
according to Infectious Diseases Society of America/American Thoracic Society consensus
guidelines on the management of CAP in adults [11].
CAP is not considered if the patient is discharged from a hospital less than 7 days before
the current hospital admission, if the first blood culture or urinary antigen assay is
obtained more than 1 week after hospital admission, or if the patient has no clinical
diagnosis of CAP at the time of admission. Patients referred from or transferred to another
hospital are excluded.
After identification of eligible patients upon microbiological results, medical records are
reviewed using a standardized data collection questionnaire. Comorbidity is determined using
the Charlson comorbidity index [10]. Additionally, all patients are classified according to
the multimorbidity patterns proposed by Holden et al. [12]. These are:
1. arthritis, osteoporosis, other chronic pain, bladder problems, and irritable bowel;
2. asthma, chronic obstructive pulmonary disease, and allergies;
3. back/neck pain, migraine, other chronic pain, and arthritis;
4. high blood pressure, high cholesterol, obesity, diabetes, and fatigue;
5. cardiovascular disease, diabetes, fatigue, high blood pressure, high cholesterol, and
arthritis; and
6. irritable bowel, ulcer, heartburn, and other chronic pain.
Time calculation is based upon the moment of emergency room (ER) admission.
;
Observational Model: Case-Only, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05722938 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
|
Phase 3 | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Recruiting |
NCT06065618 -
Characteristics of Hospitalized Patients With Community-acquired Pneumonia
|
||
Not yet recruiting |
NCT03675178 -
Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia
|
Phase 4 | |
Not yet recruiting |
NCT04166110 -
Antibiotic Therapy In Respiratory Tract Infections
|
N/A | |
Completed |
NCT02380352 -
Short-course Antimicrobial Therapy for Paediatric Respiratory Infections
|
Phase 4 | |
Completed |
NCT01671280 -
Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
|
N/A | |
Completed |
NCT02555852 -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
|
N/A | |
Recruiting |
NCT00752947 -
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
|
Phase 4 | |
Completed |
NCT00140023 -
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
|
Phase 3 | |
Recruiting |
NCT04089787 -
Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia
|
Phase 4 | |
Completed |
NCT05356494 -
Postural Drainage and PEP Technique in Community Acquired Pneumonia
|
N/A | |
Completed |
NCT05133752 -
Oral Nemonoxacin in Treating Elderly Patients With CAP
|
Phase 4 | |
Not yet recruiting |
NCT06291012 -
Stopping Pneumonia Antibiotherapy Regimen Early
|
Phase 4 | |
Recruiting |
NCT05002192 -
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
|
||
Completed |
NCT03452826 -
Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia
|
N/A | |
Terminated |
NCT04071041 -
Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.
|
Phase 3 | |
Completed |
NCT03474991 -
KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP
|
Phase 3 | |
Completed |
NCT01723644 -
Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia
|
N/A | |
Withdrawn |
NCT01662258 -
Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP
|
N/A |